Skip links

Latest Data from Guy’s Trial Endorses EMDA

Latest data from Guy’s & St Thomas’ endorses intravesical sequential BCG/EMDA+MMC for HR-NMIBC

Recent data presented by the Urology group from Guy’s & St Thomas’ NHS Foundation Trust in London, suggests that the use of a sequential intravesical regimen of BCG/EMDA+MMC after TURBT may be a useful alternative strategy in bladder preservation for HR-NMIBC patients who fail BCG.

The study cites: “This is twice the efficacy quoted for intravesical BCG alone and adds further weight to the adoption of this sequential regimen in bladder preservation for HR-NMIBC.”1

Clinicians interested in discussing the benefits of EMDA treatment for their patients should contact Murat Celebi, Clinical Marketing Director, on +44 (0)1234-888955 or by email via


1 Event Abstract: Front. Oncol. Conference Abstract: Bladder Cancer Translational Research Meeting. doi: 10.3389/conf.fonc.2019.01.00015